List of investigational fibromyalgia drugs

This is a list of investigational fibromyalgia drugs, or drugs that are currently under development for clinical use in the treatment of fibromyalgia but are not yet approved.

Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action [Reference]".

This list was last comprehensively updated in September 2025. It is likely to become outdated with time.

Under development

Preregistration

  • Esreboxetine ((S,S)-Reboxetine; AXS-14; PNU-165442G) – norepinephrine reuptake inhibitor (NRI) [1]

Phase 3

  • Pregabalin controlled release (GRO-12; Lyrica CR; Pregabalin CR; Pregabalin ER) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel ligand) [2]

Phase 2

  • Celecoxib/famciclovir (famciclovir/celecoxib; IMC-1) – combination of celecoxib (COX inhibitor/NSAID) and famciclovir (antiviral) [3]
  • Mirtazapine (Avanza; Azamianserin; ME-2040; Mepirzapin; Norset; ORG-3770; Promyrtil; Reflex; Remergil; Remergon; Remeron; Rexer; Zispin) – tetracyclic antidepressant (TeCA) (non-selective monoamine receptor modulator and other actions) [4]
  • ONO-1110 – cannabinoid receptor modulator [5]
  • Opiranserin (Unafra; VVZ-000149; VVZ-149) – glycine transporter 2 (GlyT2) blocker, purine P2X3 receptor antagonist, and serotonin 5-HT2A receptor antagonist [6]
  • Psilocybin (PFN™; TRP-8802; TRP-8803; TRP-8804; TRYP-0082) – non-selective serotonin receptor agonist and psychedelic hallucinogen [7][1][2]
  • Rozanolixizumab (Rystiggo; UCB-7665) – monoclonal antibody against neonatal Fc receptor (FcRn) [8]

Research

  • Celecoxib/valacyclovir (IMC-2; valacyclovir/celecoxib) – combination of celecoxib (COX inhibitor/NSAID) and valacyclovir (antiviral) [9]

Not under development

Suspended

  • ETX-155 – GABAA receptor positive allosteric modulator and neurosteroid [10]

No development reported

  • ASP-0819 (ASP0819) – calcium-activated potassium channel opener [11]
  • CT-38 – corticotropin-releasing factor CRF2 receptor agonist [12]
  • Elcubragistat (ABX-1431; Lu-AG06466) – monoacylglycerol lipase (MAGL) inhibitor [13]
  • Galcanezumab (Emgality; LY-2951742) – monoclonal antibody against calcitonin gene-related peptide (CGRP) [14]
  • Lacosamide (ADD-234037; Erlosamide; Harkoseride; SPM-927; SPM-929; Vimpat; Vimpato) – various actions [15]
  • Pregabalin controlled release (Pregabalin XR; Regabatin XR) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel ligand) [16]
  • Research programme: cannabis extract therapeutics - Cannabis Science – cannabinoid receptor modulators [17]
  • Research programme: pregabalin gastric-retentive - ProTect (NPRx-1000; PRTT-200) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel ligand) [18]
  • Ropinirole (Adartrel; Repreve; Requip) – dopamine D2, D3, and D4 receptor agonist [19]
  • SER-282 – undefined mechanism of action [20]
  • Somatropin (Nutrophin; Nutropin; SMP-140) – growth hormone (GH) replacement [21]
  • Sunobinop (IMB-115; IT-1315; RSC-117957; S-117957; V-117957) – nociceptin receptor agonist [22]

Discontinued

  • AD-337 – serotonin–norepinephrine reuptake inhibitor (SNRI) [23]
  • Ampreloxetine (TD-9855) – serotonin–norepinephrine reuptake inhibitor (SNRI) [24]
  • ASP-8062 – GABAB receptor positive allosteric modulator [25]
  • Desvenlafaxine (DVS-233; MD-120; O-desmethylvenlafaxine; Pristiq; WY-45233) – serotonin–norepinephrine reuptake inhibitor (SNRI) [26]
  • Droxidopa (3,4-dihydroxyphenylserine; 3,4-threo-DOPS; DOPS; Northera; threo-DOPS) – norepinephrine precursor and indirect non-selective adrenergic receptor agonist [27]
  • Eslicarbazepine acetate (Aptiom; BIA 2-093; ESL; Exalief; SEP-0002093; SEP-2093; Stedesa; Zebinix) – sodium channel blocker [28]
  • Faxeladol (GRT-9906; GRT9906) – μ-opioid receptor (MOR) agonist and serotonin–norepinephrine reuptake inhibitor (SNRI) (tramadol analogue) [29]
  • Fremanezumab (Ajovy; LBR-101; PF-04427429; PF-4427429; RN-307; TEV-48125) – monoclonal antibody against calcitonin gene-related peptide (CGRP) [30]
  • Galantamine (galanthamine; GP-37267; Nivalin; R-113675; Razadyne; Reminyl) – acetylcholinesterase inhibitor [31]
  • Ibutamoren (L-163191; LUM-201; MK-0677; MK-677; Oratrope) – ghrelin receptor agonist and growth hormone secretagogue [32]
  • Interferon α2a (IFN-α lozenges; MOR-22; Veldona) – interferon α stimulant and immunomodulator [33]
  • Nabilone (Cesamet) – cannabinoid CB1 and CB2 receptor agonist [34]
  • PF-738502 – undefined mechanism of action [35]
  • Pramipexole (BI-Sifrol; Daquiran; Mirapex; Mirapexin; Pexola; Sifrol; SND-919; SND-919Y) – dopamine D2, D3, and D4 receptor agonist [36]
  • Pregabalin sustained release (EASOPSRTFP) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel ligand) [37]
  • Radafaxine (GW-353162; (2S,3S)-hydroxybupropion) – norepinephrine–dopamine reuptake inhibitor (NDRI) [38]
  • Research programme: fibromyalgia therapies - Cypress Bioscience/Georgetown University – undefined mechanism of action [39]
  • Rotigotine transdermal (Leganto; N-0437; N-0923; Neupro; Nubrenza; SPM-962) – non-selective dopamine receptor agonist and other actions [40]
  • Sodium oxybate (γ-hydroxybutyrate; GHB; JZP-6; KEY-10; Xyrem) – GABAB receptor agonist and GHB receptor agonist [41][3][4]
  • Terguride (Dironyl; Mysalfon; SH-406; Teluron; Transdihydrolisuride; VUFB-6638; ZK-31224) – non-selective dopamine receptor agonist, non-selective serotonin receptor modulator, and other actions [42]
  • Tizanidine (AN-021A; AN-021; DS-103282-CH; DS-103282; Sirdalud; Ternelin; Zanaflex) – α2-adrenergic receptor agonist [43]
  • Ubidecarenone (Bio-Quinone Q10; Coenzyme Q10; CoQ10; Neuquinon; Q-Gel; UbiQGel; Ubiquinone; Vitaline) – antioxidant and immunomodulator [44]
  • ZYN-001 (δ9-THC D-glyceric acid ester; THC prodrug transdermal patch) – cannabinoid CB1 and CB2 receptor agonist [45]

Clinically used drugs

Approved

  • Cyclobenzaprine (KRL-102; TNX-102; Tonmya) – tricyclic antidepressant (TCA) (non-selective monoamine reuptake inhibitor and monoamine receptor modulator) [46]
  • Duloxetine (Ariclaim; Cymbalta; LY-227942; LY-248686; Xeristar; Yentreve) – serotonin–norepinephrine reuptake inhibitor (SNRI) [47]
  • Milnacipran (Dalcipran; F-2207; Impulsor; Ixel; Joncia; Midacipran; Midalcipran; Savella; TN-912; Toledomin) – serotonin–norepinephrine reuptake inhibitor (SNRI) [48]
  • Pregabalin (CI-1008; isobutylgaba; Lyrica; PD-144723) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel ligand) [49]

Off-label drugs

See also

References

  1. ^ Aday JS, McAfee J, Conroy DA, Hosanagar A, Tarnal V, Weston C, Scott K, Horowitz D, Geller J, Harte SE, Pouyan N, Glynos NG, Baker AK, Guss J, Davis AK, Burgess HJ, Mashour GA, Clauw DJ, Boehnke KF (2025). "Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial". Frontiers in Pain Research. 6 1527783. doi:10.3389/fpain.2025.1527783. PMC 11958999. PMID 40171515.
  2. ^ Czopek A, Jończyk J, Fryc M, Kluzik D, Zagórska A (June 2025). "Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives". ACS Chemical Neuroscience. 16 (12): 2163–2177. doi:10.1021/acschemneuro.5c00152. PMC 12183689. PMID 40474592.
  3. ^ a b Staud R (August 2011). "Sodium oxybate for the treatment of fibromyalgia". Expert Opin Pharmacother. 12 (11): 1789–1798. doi:10.1517/14656566.2011.589836. PMID 21679091.
  4. ^ a b Swick TJ (August 2011). "Sodium oxybate: a potential new pharmacological option for the treatment of fibromyalgia syndrome". Ther Adv Musculoskelet Dis. 3 (4): 167–178. doi:10.1177/1759720X11411599. PMC 3382678. PMID 22870476.
  5. ^ a b c d e Ram PR, Jeyaraman M, Jeyaraman N, Nallakumarasamy A, Khanna M, Gupta A, Yadav S (October 2023). "Beyond the Pain: A Systematic Narrative Review of the Latest Advancements in Fibromyalgia Treatment". Cureus. 15 (10) e48032. doi:10.7759/cureus.48032. PMC 10687844. PMID 38034135.
  6. ^ Bourke SL, Schlag AK, O'Sullivan SE, Nutt DJ, Finn DP (December 2022). "Cannabinoids and the endocannabinoid system in fibromyalgia: A review of preclinical and clinical research". Pharmacol Ther. 240 108216. doi:10.1016/j.pharmthera.2022.108216. PMID 35609718.
  7. ^ Elijah J, Powell K, Smith MA (June 2022). "The Efficacy of Capsaicin on Sleep Quality and Fatigue in Fibromyalgia". J Pain Palliat Care Pharmacother. 36 (2): 112–116. doi:10.1080/15360288.2022.2063468. PMID 35471125.
  8. ^ a b c d Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, Choy E, Kosek E, Amris K, Branco J, Dincer F, Leino-Arjas P, Longley K, McCarthy GM, Makri S, Perrot S, Sarzi-Puttini P, Taylor A, Jones GT (February 2017). "EULAR revised recommendations for the management of fibromyalgia". Ann Rheum Dis. 76 (2): 318–328. doi:10.1136/annrheumdis-2016-209724. hdl:11655/13965. PMID 27377815.
  9. ^ Thorpe J, Shum B, Moore RA, Wiffen PJ, Gilron I (February 2018). "Combination pharmacotherapy for the treatment of fibromyalgia in adults". Cochrane Database Syst Rev. 2 (2) CD010585. doi:10.1002/14651858.CD010585.pub2. PMC 6491103. PMID 29457627.
  10. ^ Vaerøy H, Abrahamsen A, Førre O, Kåss E (June 1989). "Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp) versus placebo". Clin Rheumatol. 8 (2): 245–250. doi:10.1007/BF02030081. PMID 2667860.
  11. ^ a b c d e Sarzi-Puttini P, Giorgi V, Marotto D, Atzeni F (November 2020). "Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment". Nat Rev Rheumatol. 16 (11): 645–660. doi:10.1038/s41584-020-00506-w. PMID 33024295.
  12. ^ Cooper TE, Derry S, Wiffen PJ, Moore RA (January 2017). "Gabapentin for fibromyalgia pain in adults". Cochrane Database Syst Rev. 1 (1) CD012188. doi:10.1002/14651858.CD012188.pub2. PMC 6465053. PMID 28045473.
  13. ^ Hemati K, Amini Kadijani A, Sayehmiri F, Mehrzadi S, Zabihiyeganeh M, Hosseinzadeh A, Mirzaei A (February 2020). "Melatonin in the treatment of fibromyalgia symptoms: A systematic review". Complement Ther Clin Pract. 38 101072. doi:10.1016/j.ctcp.2019.101072. PMID 31783341.
  14. ^ Tort S, Urrútia G, Nishishinya MB, Walitt B (April 2012). "Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome". Cochrane Database Syst Rev. 2012 (4) CD009807. doi:10.1002/14651858.CD009807. PMC 11729144. PMID 22513976.
  15. ^ Welsch P, Bernardy K, Derry S, Moore RA, Häuser W (August 2018). "Mirtazapine for fibromyalgia in adults". Cochrane Database Syst Rev. 8 (8) CD012708. doi:10.1002/14651858.CD012708.pub2. PMC 6513659. PMID 30080242.
  16. ^ MacLean AJ, Schwartz TL (May 2015). "Tramadol for the treatment of fibromyalgia". Expert Rev Neurother. 15 (5): 469–475. doi:10.1586/14737175.2015.1034693. PMID 25896486.
  17. ^ da Rocha AP, Mizzaci CC, Nunes Pinto AC, da Silva Vieira AG, Civile V, Trevisani VF (March 2020). "Tramadol for management of fibromyalgia pain and symptoms: Systematic review". Int J Clin Pract. 74 (3) e13455. doi:10.1111/ijcp.13455. PMID 31799728.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.